2. Baseline characteristics and diagnostic criteria ‐ included studies.
| Trial | dementia criteria | depression criteria | number of patients | duration | intervention | mean age | mean MMSE | mean depression rating scale score |
| An 2017 | NINCDS‐ADRDA for AD | three or more from Olin's criteria for depression in AD | 84 | 8 weeks | 5 mg/day of escitalopram, increased 5 mg/day every two weeks, up to a maximum dosage of 15 mg/day | 75.2 (6.9) | 18.85 | CSDD: 11.39 |
| Banerjee 2011 | NINCDS‐ADRDA for probable or possible AD | depression ≥ 4 weeks's duration potentially needing antidepressants; CSDD ≥ 8 | 326 | 39 weeks | sertraline 70 mg/d (target dose: 150 mg/d), mirtazapine 24 mg/d (target dose: 45 mg/d) | 79.3 | 18.1 | CSDD: 12.9 |
| de Vasconcelos 2007 | DSM‐IV for dementia (AD, VD, and mixed) | DSM‐IV major depressive disorder and CSDD | 31 | 6 weeks | venlafaxine (37.5‐131.25 mg/d, mean = 75 mg/d) | 77.6 (6.4) | (range: 10‐24) | MADRS: 24.5 (7.1) |
| Fuchs 1993 | DSM‐III‐R for PDD | DSM‐III‐R 290.21(mildly depressed) | 127 | 8 weeks | maprotiline (25 mg titrated to 75 mg/d, mean max. dose 59 mg/d) | 80 (48‐96) | 15.4 (0‐30) | GDS (median): 8 |
| Lyketsos 2003 | NINCDS‐ADRDA for probable AD | DSM‐VI for major depressive episode | 44 | 12 weeks | sertraline (25 mg titrated to 150 mg/d, mean peak dose 113 mg) | 77.7 | 16.9 | Ham‐D: 22.75 |
| Petracca 1996 | NINCDS‐ADRDA for probable AD | DSM‐III‐R for dysthymia or major depression | 24 | 6 weeks + 6 weeks | clomipramine (25 mg titrated to 100 mg/d) | 72 (7.2) | 21.5 (6.2) | Ham‐D:17.5 (6.0) |
| Petracca 2001 | NINCDS‐ADRDA for probable AD | DSM‐IV criteria for either major or minor depression | 41 | 6 weeks | fluoxetine (10 mg titrated to 40 mg/d) | 70.8 | 23.2 | Ham‐D: 16.5 |
| Reifler 1989 | DSM‐III for PDD | DSM‐III (major depressive disorder) | 28 | 8 weeks | imipramine (mean dose 83 mg/d) | 72 (8) | 17.5 (5.1) | Ham‐D: 18.9 (3.8) |
| Rosenberg 2010 | DSM‐IV for AD | Criteria for depression of AD | 131 | 12 weeks | sertraline 50 mg/d increased to 100 mg/d, mean = 93.1 mg/d) | 77.3 (8.0) | 20.0 (4.6) | CSDD (median): 13 (1st and 3rd quartile: 9, 18) |
| Roth 1996 | DSM‐III for dementia | DSM‐III for major depressive episode | 726 | 6 weeks | moclobemide (400 mg/d) | 74.4 (8.5) | 20.2 (4.8) | 24.5 (5.3) |
|
Weintraub 2010 (extension of Rosenberg 2010) |
DSM‐IV for AD | Criteria for depression of AD | 131 | 24 weeks | randomised treatment with sertraline for at least partial responders after week 12 | 77.3 (8.0) | 20.0 (4.6) | CSDD (median): 13 (1st and 3rd quartile: 9, 18) |